The Association Between BMI Measured Within a Year After Diagnosis of Type 2 Diabetes and Mortality by Logue, Jennifer et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Association Between BMI Measured Within a Year After
Diagnosis of Type 2 Diabetes and Mortality
Citation for published version:
Logue, J, Walker, JJ, Leese, G, Lindsay, R, McKnight, J, Morris, A, Philip, S, Wild, S, Sattar, N & on behalf
of The Scottish Diabetes Research Network Epidemiology Group 2013, 'The Association Between BMI
Measured Within a Year After Diagnosis of Type 2 Diabetes and Mortality' Diabetes Care, vol 36, no. 4, pp.
887-893., 10.2337/dc12-0944
Digital Object Identifier (DOI):
10.2337/dc12-0944
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Diabetes Care
Publisher Rights Statement:
    © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and
the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Association Between BMIMeasured
Within a Year After Diagnosis of Type 2
Diabetes andMortality
JENNIFER LOGUE, MD1
JEREMY J. WALKER, PHD2
GRAHAM LEESE, MD3
ROBERT LINDSAY, PHD1
JOHN MCKNIGHT, MD4
ANDREW MORRIS, MD3
SAM PHILIP, MD5
SARAH WILD, FRCP2
NAVEED SATTAR, FRCP1
ON BEHALF OF THE SCOTTISH DIABETES
RESEARCH NETWORK EPIDEMIOLOGY
GROUP*
OBJECTIVEdTo describe the association of BMI with mortality in patients diagnosed with
type 2 diabetes.
RESEARCHDESIGNANDMETHODSdUsing records of 106,640 patients in Scotland,
we investigated the association between BMI recorded around the diagnosis of type 2 diabetes
mellitus (T2DM) and mortality using Cox proportional hazards regression adjusted for age and
smoking status, with BMI 25 to ,30 kg/m2 as a referent group. Deaths within 2 years of BMI
determination were excluded. Mean follow-up to death or the end of 2007 was 4.7 years.
RESULTSdA total of 9,631 deaths occurred between 2001 and 2007. Compared with the ref-
erence group, mortality risk was higher in patients with BMI 20 to,25 kg/m2 (hazard ratio 1.22
[95% CI 1.13–1.32] in men, 1.32 [1.22–1.44] in women) and patients with BMI$35 kg/m2 (for
example, 1.70 [1.24–2.34] in men and 1.81 [1.46–2.24] in women for BMI 45 to ,50 kg/m2).
Vascular mortality was higher for each 5-kg/m2 increase in BMI.30 kg/m2 by 24% (15–35%) in
men and 23% (14–32%) in women, but was lower below this threshold. The results were similar
after further adjustment for HbA1c, year of diagnosis, lipids, blood pressure, and socioeconomic
status.
CONCLUSIONSdPatients categorized as normal weight or obese with T2DM within a year
of diagnosis of T2DM exhibit variably higher mortality outcomes compared with the overweight
group, conﬁrming a U-shaped association of BMI with mortality. Whether weight loss interven-
tions reduce mortality in all T2DM patients requires study.
Diabetes Care 36:887–893, 2013
Compared with normal weight, obe-sity is associated with increasedall-cause mortality in the general
population, as well as increased cardio-
vascular and cancer mortality (excluding
smoking-related cancers) (1–3). How-
ever, the ﬁndings in patients with type 2
diabetes mellitus (T2DM) have been vari-
able, with some studies reporting an
increase in all-cause mortality with
increasing body mass (4–6), but many
studies ﬁnding no relationship (7–10)
or a decrease in mortality with higher
BMI (11). This may be due to limited
power, as those studies describing no as-
sociation all included,1,000 individuals
(7–10) and limitations of the analytical
approaches. In the general population,
the relationship between BMI andmortal-
ity is U-shaped (1) with excess mortality
seen at BMI,22.5 kg/m2 compared with
22.5–25 kg/m2. Consequently, if the low-
est BMI group is used as the reference
group, excess mortality in the obese range
compared with the BMI group with the
lowest mortality (i.e., the low normal
range) is not always apparent. There is
also the potential for reverse causality
as a consequence of another medical con-
dition causing both weight loss and death
and confounding by smoking, which can
lead to smokers having a lower BMI than
nonsmokers yet a high risk of smoking-
related disease. Higher BMI is associated
with increased risk of coronary heart dis-
ease and cardiovascular mortality among
people with T2DM (6,12), in keeping
with results from the general population.
As these studies (4–11) represent cross-
sections of populations with established
T2DM, there is the potential that diabetes
control, treatment, and duration will have
inﬂuenced BMI. These complexities and
conﬂicting results have in some way de-
ﬂected attention from the potential im-
portance of weight reduction in patients
with diabetes.
The aim of the present work, based on
data from the Scottish Care Information
Diabetes Collaboration (SCI-DC) data-
base, was to examine the relationship
between BMI within a year after diagnosis
of T2DM and all-cause, cardiovascular,
cancer, and respiratory mortality in the
medium term. The use of a large contem-
porary database has allowed closer exam-
ination of any graded association between
obesity and mortality than among smaller
studies. The availability of BMI recorded
within a year after diagnosis limits the
potential effects that diabetes treatment
and glycemic control can have on BMI.
RESEARCH DESIGN AND
METHODS
Data collection
Data were drawn from a 2008 extract of
the SCI-DC dataset, a dynamic clinical
database that was started on a national
basis in 2000 and included retrospective
data collation where available. Complete-
ness increased up to 2004, after which we
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estimate that that data were derived from
all hospitals, and all except 5 of ;1,000
general practitioners are downloaded to
SCI-DC on a daily basis, representing
data from .99% of people with diag-
nosed diabetes in Scotland. Generation
of the linked dataset was approved by
the SCI-DC steering committee, the Scot-
tish Multicenter Research ethics commit-
tee, the Privacy Advisory Committee of
National Health Service (NHS) National
Services Scotland, and data protection
guardians of all Health Boards in Scot-
land. The research database is pseu-
donymized. Inclusion criteria for this
analysis included a diagnosis of T2DM, a
measurement of BMI recorded within 1
year after diagnosis of diabetes, and data
available for year of birth and sex. Patients
with BMI recorded after the study end
point (31 December 2007) were ex-
cluded, as were those aged ,30 years
when diagnosed with diabetes. Com-
pleteness of BMI data has increased over
time from 40% in 2001 to 85% in 2007
(13). Other characteristics recorded
within 1 year of diagnosis of diabetes
that were investigated included total cho-
lesterol, HDL, HbA1c, blood pressure,
smoking status, and an area-based mea-
sure of socioeconomic status (quintiles of
the Scottish Index of Multiple Depriva-
tion [SIMD]). The SIMD combines 38 in-
dicators across seven domains, namely:
income, employment, health, education,
skills and training, housing, geographic
access, and crime and provides a relative
measure of deprivation that can be used to
compare data zones by providing a rela-
tive ranking from most deprived to least
deprived (14). Where multiple measure-
ments were recorded within 1 year after
diagnosis of T2DM, the chronologically
earliest to diagnosis of T2DM was used.
The SCI-DC data extract was linked
by the Information Services Division of
NHS National Services Scotland to mor-
tality records held by the National Re-
cords of Scotland. An independent check
of the quality of linkages carried out by
the Scottish record linkage team found
that there was a false-positive (incorrect
links) rate of 3.7% and a false-negative
(missed links) rate of 1.9% between two
incidence databases in a study of 3,077
subjects (15). Causes of death were aggre-
gated into disease groups: vascular (ICD-9
codes 350–459 and 798; ICD-10 codes
I00–I99); respiratory (ICD-9 010–012
and 460–519; ICD-10 J00–J99); can-
cers of lung, mouth, larynx, pharynx,
and esophagus (ICD-9 140–150 and
160–165; ICD-10 C00–C15 and C30–
C39); and other malignant neoplasm
(ICD-9 151–159 and 166–208; ICD-10
C16–C29 and C40–C97). Patients who
died within 2 years of index BMI recording
were excluded from the study to limit pos-
sible biases attributable to reverse causa-
tion. Cause of death was attributed in a
hierarchical fashion from both the primary
and secondary causes of death. Firstly, if a
cancer of the lung,mouth, larynx, pharynx,
or esophagus or any other malignant neo-
plasm was listed as either the primary or
secondary cause, this was recorded as the
cause of death. Secondly, if no cancer was
listed but any vascular code was listed, this
was recorded as the cause of death. Thirdly,
if no cancer or vascular code was listed but
any respiratory codewas, this was recorded
as the cause of death. Deaths not ﬁtting the
above criteria were excluded from
the cause-speciﬁcmortality analyses but in-
cluded in all-cause mortality analyses.
Statistical analyses
Previous studies (1) have demonstrated
convincingly that all-cause mortality
does not increase monotonically with
greater BMI but instead follows a U-shaped
pattern. Because of this, estimation of a
single hazard ratio (HR) across the full
range of BMI values is potentially mislead-
ing. Recognizing this, and in accordance
with the approach by others, we elected to
use the category with the largest numbers
of individuals (BMI 25–30 kg/m2) as the
reference category for all-cause mortality
and to model the inﬂuence of BMI on
cause-speciﬁc mortality separately for
low and high BMI subsets of the sample
(corresponding, respectively, to the lower
and upper extremes of the anticipated
U-shaped pattern). Associations between
BMI and mortality, all-cause and cause-
speciﬁc, were investigated using Cox pro-
portional hazards regression. The models
were restricted to people with BMI
values in the range 20 to ,50 kg/m2 due
to small numbers outside this range. For
all-cause mortality, patients were grouped
into 5 kg/m2 BMI categories from 20 to
,50 kg/m2 and HRs for BMI were esti-
mated relative to the reference group of
25 to,30 kg/m2. Estimates were adjusted
for the effects of age at BMI determination
and for smoking status chronologically
closest to the point of BMI determination
(current or former smoker vs. never
smoker). Models were ﬁtted separately
for each sex.
For cause-speciﬁc mortality, patients
were classiﬁed as either low BMI (20 to
,30 kg/m2) or high BMI (30 to ,50 kg/
m2). This mirrored the approach used in a
recent major study (1). For each group,
the HR associated with an increase of 5
kg/m2 was estimated, adjusted for age
and smoking status. Associations be-
tween BMI groups and available risk
factors were assessed either via a Kruskal-
Wallis test (for continuous quantities: to-
tal cholesterol/HDL-cholesterol/HbA1c/
blood pressure/age) or via the Mantel-
Haenszel x2 test. The Kruskal-Wallis test
was used in preference to ANOVA be-
cause the assumption of equal variances
in all BMI groups was unsafe in some
cases.
RESULTSdThe analyses were based on
106,640 individuals for whom an index
BMI measurement taken within 1 year
after diagnosis of diabetes, and on or
before the study end point, was available.
Major reasons for exclusion were: death
within 2 years of the index BMI measure-
ment being recorded (N = 11,510); no in-
dex BMI measurement being available
within 1 year of diagnosis with diabetes
(N = 94,250); the index BMI value being
outside thepermitted range ($20kg/m2 and
,50 kg/m2; N = 4,992); and smoking sta-
tus not being available (N = 1,812). A full
case-ﬂow schedule is given in Supplemen-
tary Fig. 1. Overall, 106,640 of 240,648
people (44.3%) with T2DM were eligible
for inclusion in the present analysis. The
median time in notional months (1
month = 30 days) between the date of di-
agnosis of diabetes and date of the index
BMI measurement was 1.67 (interquartile
range 3.90) for men (n = 58,372) and 1.8
(interquartile range 4.03) for women (n =
48,268). A total of 14.0% of men and
13.1% of women had BMI recorded on
the date of diagnosis of diabetes. Charac-
teristics of the 133,929 patients excluded
are given in Supplementary Table 1; miss-
ing data were the principal reason for
exclusion, although where baseline char-
acteristics were available, they were
broadly similar with those for people in-
cluded in the analysis. Supplementary
Table 2 gives the age and SIMD for those
excluded due to no BMI data being avail-
able, available BMI being measured out-
side 1 year from diagnosis of T2DM, and
those who were included; those with
BMI outside of 1 year after diagnosis
were slightly younger than patients in-
cluded in analysis, who in turnweremark-
edly younger than people with no BMI
data at all. The analyses included 58,372
men (among whom 5,272 deaths were
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observed) and 48,268 women (4,359
deaths). Mean follow-up (from date of
BMI determination to death or 31 Decem-
ber 2007) for men was 4.6 years (SD 3.3
years) and for women was 4.7 years (SD
3.3 years). There were 269,788 person-
years of follow-up for men, 5,272 deaths,
and 19.5 deaths/1,000 person-years. For
women, there were 227,857 person-years
of follow-up, 4,359 deaths, and 19.1
deaths/1,000 person-years. The distribu-
tions of index BMI measurements by year
of recording are shown in Supplementary
Fig. 2; 1% ofmeasurements were recorded
prior to 1968. A total of 89.6% of all di-
agnoses of T2DM were made during
1998–2007.
Baseline characteristics (i.e., those
recorded closest to diagnosis of diabetes)
of the study population by BMI category
are described in Table 1 (men) and Table
2 (women). In men, the results were as
expected, with decreasing age and HDL-
cholesterol and increasing total choles-
terol and systolic and diastolic blood
pressure as BMI increases (all P ,
0.001). There was a U-shaped relation-
ship between HbA1c and BMI among
men. Smoking prevalence decreased
with increasing BMI, and there were
higher proportions of men from the
more deprived quintiles in higher than
lower BMI categories (both P , 0.001).
For women, the same trends exist for
HDL-cholesterol, age, SIMD, diastolic
blood pressure, systolic blood pressure,
and smoking (all P , 0.001). An excep-
tion was HbA1c, which was slightly higher
among the lower two BMI groups than
other BMI groups, although between-
group differences in HbA1c were not sta-
tistically signiﬁcant.
Ethnicity was poorly recorded in the
dataset: 34.9% of males and 35.0% of
females had ethnicity recorded. Of those
with recorded ethnicity, 95.1% of males
and 95.6% of females were classiﬁed as
white, consistent with the ethnic distri-
bution of the general population of Scot-
land.
BMI within a year after diagnosis
and mortality
There was a U-shaped relationship be-
tween BMI at the time of diagnosis of
T2DM and all-cause mortality in both
men and women (Fig. 1 and Table 3). In
both sexes, there was a higher risk of mor-
tality at BMI 20 to ,25 kg/m2 relative to
BMI 25 to,30 kg/m2 (age- and smoking-
adjusted HR 1.22 [95% CI 1.13–1.32] in
men and 1.32 [1.22–1.44] in women).
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Risk of mortality increased with increas-
ing BMI .35 kg/m2, with the risk of
mortality 70% higher in men (1.70
[1.24–2.34]) and 81% higher in women
(1.81 [1.46–2.24]) with a BMI of 45–50
kg/m2 compared BMI of 25 to ,30 kg/m2.
For each 5 kg/m2 increase in BMI from 30
to ,50 kg/m2, the risk of mortality
increased by 16% in women (1.16
[1.10–1.22]) and 21% in men (1.21
[1.14–1.29]). These data were analyzed
separately for smokers and nonsmokers,
and the ﬁndings were unchanged (Supple-
mentary Table 3).
Cause-speciﬁc mortality
Table 4 shows the HRs for cause-speciﬁc
mortality by BMI and sex. The U-shaped
relationship seen for all-cause mortality
persists for vascular and respiratory mor-
tality in both sexes, but was more pro-
nounced in men than women. There is
also an increased risk of mortality from
non-aerodigestive tract cancers in men
as BMI increases .30 kg/m2, but not be-
low it. Of particular note was a strikingly
lower risk of mortality from respiratory
disease for each 5-kg/m2 increase in BMI
from 20 to,30 kg/m2 in both sexes, with
an identical increased risk of respiratory
mortality in men for each 5-kg/m2 in-
crease in BMI from 30 to ,50 kg/m2
and with broadly similar ﬁndings in
women. Risk of vascular mortality in-
creased by 23% for each 5-kg/m2 increase
in BMI from 30 to ,50 kg/m2 in women
(HR 1.23 [95% CI 1.14–1.32]) and 24%
in men (1.24 [1.15–1.35]).
To investigate the possible biases
attributable to reverse causation (that is,
low BMI due to pre-existing disease re-
sulting in increased mortality), sensitivity
analyses were conducted excluding no
deaths and those within 2 and 5 years
after BMI determination. There was little
difference seen in the pattern of results
when no deaths were excluded compared
with deaths within 2 and 5 years of BMI
determination (Supplementary Table 4).
To determine whether the survival
experience of those excluded from the
study was materially different from that of
the patients who were included, addi-
tional Cox models were ﬁtted including
those originally excluded from the anal-
ysis. In these models, survival was pre-
dicted by age (at diagnosis of diabetes),
SIMD quintile, and inclusion status (ex-
cluded due to no available BMI, excluded
due to no BMI recordedwithin 1 year post
diagnosis with diabetes, or included in
the study). Start of follow-up was deﬁnedT
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as the date of diagnosis and patients who
died within 2 years of being diagnosed
with diabetes were excluded. The validity
of the proportional hazards assumption
for these models was assessed via log
(2log[survival]) plots (16,17) (Supple-
mentary Fig. 3A and B). No gross depar-
ture from proportionality of hazard was
seen. HRs for those excluded due to hav-
ing no BMI data at all (relative to those
included in the study) are 2.06 (95% CI
1.97–2.14) for men and 1.84 (1.76–1.91)
for women. Corresponding values for pa-
tients excluded due to not having a BMI
measurement taken within 1 year of di-
agnosis with diabetes are 0.76 (0.74–
0.79) for men and 0.77 (0.74–0.80) for
women. It thus appears that patients who
were ineligible for inclusion in the
original analysis due to their having no
BMI within 1 year postdiabetes had a bet-
ter survival experience than those who
were included, whereas those with no
BMI data at all exhibited poorer survival
than those featured in the reported anal-
ysis.
Sensitivity analyses were conducted
to investigate the potential confounding
or mediating effects of HbA1c, SIMD, year
of diagnosis, total cholesterol, HDL-
cholesterol, and systolic blood pressure.
The addition of these variables to the
model did not affect the HR estimates
for effect of BMI (increase of 5 kg/m2)
on mortality from any cause (Supplemen-
tary Table 5). As data on these variables
were not available for the full cohort, an
analysis was performed using only those
individuals with data available for all of the
potential confounding/mediating factors
listed above; this again showed no attenu-
ation of the effect of BMI on all-cause mor-
tality (results available on request).
CONCLUSIONSdResults from this
large population-based T2DM cohort
show that individuals with class II obesity
or greater (BMI .35 kg/m2) and those of
normal weight (BMI 20 to ,25 kg/m2),
within a year after diagnosis of T2DM
have an increased risk of all-cause mortal-
ity after $2 years compared with people
with a BMI in the overweight category
(BMI 25 to ,30 kg/m2). Examination of
the association between BMI within a year
after diagnosis of diabetes and cause-
speciﬁc mortality revealed a U-shaped
curve for vascular death in both sexes
and for respiratory disease in men. There
was also increased mortality from non-
aerodigestive tract cancers in men for
each 5-kg/m2 increase in BMI from 30 to
,50 kg/m2. The use of BMI within a year
of diagnosis allowed the association to be
examined with much lower likelihood of
the confounding effects that speciﬁc treat-
ment, diabetes duration, and glycemic
control have on both bodymass andmor-
tality. The large cohort also allowed indi-
viduals who diedwithin the ﬁrst 2 years of
follow up to be excluded to limit the ef-
fects of reverse causality.
The association between BMI and
mortality has gained much attention re-
cently, with three large prospective stud-
ies of the general population (1–3). These
three studies showed broadly similar re-
sults, ﬁnding the lowest mortality at BMI
22.5 to ,25 kg/m2, which clearly con-
trasts with our ﬁnding of the lowest risk
among people with T2DM being perhaps
midway between 25 and 35 kg/m2. The
prospective studies collaboration (PSC)
(1) also examined cause-speciﬁc mortal-
ity, and we performed our analysis to al-
low comparison with these results.
Reﬂecting the fact that it is a meta-analysis
of studies of the general population, the
PSC had a mean age at recruitment of 46
years, though with a mean follow-up pe-
riod of 11 years, the mean age of death
was 67; 61% of the study population
were male. However, although the PSC
examined mortality for each 5-kg/m2
rise in BMI from 15 to ,25 kg/m2 and
25 to ,50 kg/m2, we used categories of
20 to,30 kg/m2 and 30 to,50 kg/m2. In
other words, the U-shaped association of
BMI with mortality seems to be right-
shifted in patients with T2DM.
Figure 1dHR estimates for effect of BMI on all-cause mortality. Plotted points are located at the
midpoint of the range covered by each BMI band (e.g., the point for band 25 to ,30 kg/m2 is
positioned at 27.5 on the horizontal axis). Estimates are adjusted for age at BMI determination
and smoking status. Deaths within 2 years of BMI determination are excluded. Numbers of pa-
tients (deaths) are: men, 58,372 (5,272) and women, 48,268 (4,359).
Table 3dHR estimates for effect of BMI on all-cause mortality
BMI (kg/m2) Men [HR (95% CI)] Women [HR (95% CI)]
20 to ,25 1.22 (1.13–1.32) 1.32 (1.22–1.44)
25 to ,30 [referent] 1.00 1.00
30 to ,35 0.97 (0.91–1.04) 1.04 (0.96–1.12)
35 to ,40 1.14 (1.03–1.27) 1.10 (0.99–1.21)
40 to ,45 1.34 (1.12–1.61) 1.34 (1.17–1.55)
45 to ,50 1.70 (1.24–2.34) 1.81 (1.46–2.24)
Estimates are adjusted for age at BMI determination and smoking status (never vs. current/former). Deaths
within 2 years of BMI determination are excluded. Numbers of patients (deaths) are: men, 58,372 (5,272) and
women, 48,268 (4,359).
care.diabetesjournals.org DIABETES CARE, VOLUME 36, APRIL 2013 891
Logue and Associates
The estimates of relative mortality are
remarkably similar to that of the PSC for
all-cause mortality, aerodigestive tract
cancers, other cancers, and respiratory
disease, although the PSC data are not
stratiﬁed by sex. For example, the HR for
all-cause mortality in the PSC population
was 0.79 (95% CI 0.77–0.82) per 5-kg/m2
increase in BMI (adjusted for age, sex, and
smoking status) from 15 to ,25 kg/m2
(1); in our population with T2DM, the
HR in men was 0.82 (0.76–0.88) and
women 0.77 (0.71–0.84) per 5-kg/m2 in-
crease in BMI from 20 to ,30 kg/m2.
Therefore, our results from a population-
based diabetes cohort show a very similar
pattern to those found in large general-
population studies, but with the lowest
mortality category ;5 kg/m2 higher
among people with T2DM than the gen-
eral population.
T2DM is in an obesity-related disease,
with this study population having a mean
BMI at the time of diagnosis of 31.3 kg/m2
(SD 5.7 kg/m2) (18). People who have a
lower body mass at the time of diagnosis
may have a different, potentially more ag-
gressive, pathophysiology from those
who develop it when obese: an increased
sensitivity to visceral fat accumulation, a
stronger genetic tendency to insulin resis-
tance, or early pancreatic islet failure, all
factors potentially giving a different dis-
ease phenotype associated with higher
mortality. This so called “obesity para-
dox” has been reported in chronic disea-
ses such as chronic heart failure and
coronary artery disease (19–22), with a
lower BMI associated with a more severe
disease phenotype.
The baseline characteristics of the pop-
ulation in this study show expected asso-
ciations with increasing BMI except HbA1c,
with a trend toward higher HbA1c in leaner
individuals in both sexes. The reasons be-
hind this are not known; it may be that
leaner individuals are thought less at risk
for T2DM, leading to a delay in diagnosis
and consequently more advanced disease
at diagnosis or a more aggressive pheno-
type. Such explanations might explain an
increased risk of mortality seen in the BMI
20–25 kg/m2 category. Other explanations
for increased mortality in the lower BMI
group include residual confounding factors
such as intensity of smoking and other ad-
verse lifestyle factors or a higher prevalence
of comorbid conditions at lower BMI. This
ﬁnding of an increased risk of mortality in
peoplewhohaveT2DMdiagnosed at a BMI
,25 kg/m2 is in keeping with recent ﬁnd-
ings from a smaller study by Carnethon
et al. (11).
Our observation of a right-shifted
U-shaped association of BMI with mor-
tality in T2DMpatients is interesting. This
could partly be explained by secular
trends in BMI distribution: in the general
population of Scotland the prevalence of
obesity increased from 16.9% in 1995 to
22.3% in 2003 with rising median BMI
over time (23). There has also been an
increase in life expectancy within that
time, coupled with improvements in
cardiovascular disease and diabetes man-
agement (24). However, in the work by
Pischon et al. (3) with data from 1992–
2000, the nadir of mortality risk was 25.3
kg/m2 for men and 24.3 kg/m2 for
women, values that appear still to be
much lower than results presented in
this study for people with type 2 diabetes.
Thus a right shift may be genuine and is in
keeping with the higher average BMI in
patients diagnosed with T2DM (18).
The major strength of this work was
the availability of data on a large, con-
temporary diabetes population with
available data on other cardiovascular
disease risk factors. Although missing
BMI data within 12 months of diagnosis
excluded a large proportion of individu-
als, we have no reason to believe that the
group with data available was unrepre-
sentative. We performed sensitivity anal-
yses including patients with BMI data
recorded outside of 12 months after di-
agnosis or no BMI recorded; patients with
no BMI recorded within 1 year of di-
agnosis had a better survival experience,
whereas those with no BMI data exhibited
poorer survival than those featured in the
main analysis. The reasons for these
ﬁnding remains conjectural but does not
negate the relationship seen between BMI
and mortality outcomes.
Nevertheless, we had statistical power
to examine the associations between BMI
and mortality in far greater detail than had
been done previously, including by sex and
cause of death. Unfortunately, ethnicity
was poorly recorded in this cohort. How-
ever, Scotland has a predominantly white
European population, and the ﬁndings of
this study are therefore limited to this
ethnic group. Also, the use of a single
BMImeasurement after diagnosis of T2DM
may not fully reﬂect the risk of lifetime
exposure to excess weight (25). There are
factors that may be associated with BMI
andmortality, asmediators or confounders
of risk, such as alcohol, physical activity,
and diabetes medications; however, we
did not have these data available for analy-
sis in this study. We have used SIMD as a
proxy of individual level of socioeconomic
position, as the individual units of summa-
rization are relatively small (,1,000 indi-
viduals) and therefore likely to be grossly
homogeneous; data on individual-level so-
cioeconomic position were not available.
The data used in this study span a large
period of time, and data pre-2000were col-
lected retrospectively; however, the major-
ity of the data were from post-2000, and
further statistical adjustment for year of
Table 4dHR estimates for effect of BMI (increase of 5 kg/m2 from 20 to <30 kg/m2 or
from 30 to <50 kg/m2 according to stratum) on mortality from speciﬁc causes, split by sex
Cause of death
Men
20 to ,30 kg/m2 (n = 28,643) 30 to ,50 kg/m2 (n = 29,729)
Deaths HR (95% CI) Deaths HR (95% CI)
All 3,291 0.82 (0.76–0.88) 1,981 1.21 (1.14–1.29)
Vascular 1,667 0.89 (0.80–0.99) 1,086 1.24 (1.15–1.35)
Respiratory 264 0.45 (0.35–0.58) 95 1.38 (1.05–1.81)
Cancer (lung, etc.) 356 0.77 (0.61–0.96) 208 1.08 (0.89–1.32)
Cancer (other) 738 1.02 (0.87–1.20) 448 1.14 (0.99–1.30)
Women
20 to ,30 kg/m2 (n = 20,156) 30 to ,50 kg/m2 (n = 28,112)
All 2,419 0.77 (0.71–0.84) 1,940 1.16 (1.10–1.22)
Vascular 1,333 0.80 (0.71–0.89) 1,036 1.23 (1.14–1.32)
Respiratory 204 0.60 (0.45–0.78) 141 1.27 (1.04–1.54)
Cancer (lung, etc.) 185 0.71 (0.53–0.94) 137 1.03 (0.85–1.26)
Cancer (other) 484 0.91 (0.76–1.09) 463 1.01 (0.90–1.13)
Estimates are adjusted for age at BMI recording and for smoking status (never vs. current/former). Deaths
within 2 years of BMI determination are excluded.
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diagnosis of diabetes did not alter the re-
sults or conclusions.
In summary, this study has shown a
U-shaped relationship between BMI
within a year after diagnosis of diabetes
and subsequent mortality, with BMI of 25
to ,30 kg/m2 associated with the lowest
mortality risk $2 years after diagnosis of
diabetes.Consequently, the lowestmortality
group in diabetes patients had an;5 kg/m2
higher BMI than that observed in a large
general-population study, in keeping with
the average BMI of diabetes patients being
considerably higher than average BMI for
the population. Our results, seen around
the time of diagnosis of diabetes, also sug-
gest that the mechanisms for obesity-
related mortality risk in diabetes may not
be explained by dysglycemia alone. Re-
ducing or at least stabilizing body mass
in obese patients with T2DM may poten-
tially lead to a reduction in mortality risk
beyond the beneﬁts on glycemic control
and should be considered a clinical prior-
ity. Further research is needed to investi-
gate the mechanisms of obesity-related
mortality risk, potential mechanisms for
increased mortality at lower BMI, and
also the effect of weight loss interventions
onmorbidity and mortality in people with
T2DM with differing levels of baseline
BMI.
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